NasdaqGM - Delayed Quote USD

Veracyte, Inc. (VCYT)

19.85 +0.40 (+2.06%)
At close: April 22 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Marc A. Stapley CEO & Director 1.25M -- 1970
Ms. Rebecca Chambers Executive VP & CFO 772.41k -- 1979
Ms. Annie McGuire Executive VP, General Counsel & Chief People Officer 633.65k -- 1981
Mr. Jonathan Wygant VP & Chief Accounting Officer -- -- 1971
Mr. Steven French Senior VP & Chief Information Officer -- -- --
Dr. Phillip G. Febbo M.D. Chief Scientific & Medical Officer -- -- 1966
Ms. Karen Possemato Senior Vice President of Corporate Marketing, Communications & Commercial Operations -- -- --
Mr. Robert Brainin Executive VP & Chief Business Officer -- -- 1971
Dr. John Leite Ph.D. Chief Commercial Officer for CLIA Business -- -- --
Ms. Corinne Danan Senior Vice President -- -- --

Veracyte, Inc.

6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 243 6300 https://www.veracyte.com
Sector: 
Healthcare
Full Time Employees: 
815

Description

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Corporate Governance

Veracyte, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 4; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024 - May 06, 2024
Veracyte, Inc. Earnings Call

Related Tickers

CDNA CareDx, Inc
8.17
-1.68%
 
TWST Twist Bioscience Corporation
29.45
+5.37%
 
MYGN Myriad Genetics, Inc.
18.49
-0.05%
 
PSNL Personalis, Inc.
1.2600
-2.33%
 
NTRA Natera, Inc.
88.61
+3.90%
 
XGN Exagen Inc.
1.4000
+2.19%
 
GH Guardant Health, Inc.
17.59
+9.46%
 
NEO NeoGenomics, Inc.
13.42
-0.81%
 
DVYSR.ST Devyser Diagnostics AB (publ)
105.00
+2.44%
 
EXAS Exact Sciences Corporation
62.41
+2.38%